MARKET

CERO

CERO

CERo Therapeutics
OTCMQB
0.012
-0.001
-6.98%
Opening 12:06 06/03 EDT
OPEN
0.013
PREV CLOSE
0.013
HIGH
0.013
LOW
0.011
VOLUME
287.47K
TURNOVER
3.54K
52 WEEK HIGH
895.40
52 WEEK LOW
0.011
MARKET CAP
541.35K
P/E (TTM)
-0.0002
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CERO last week (0525-0529)?
Weekly Report · 2d ago
CERo Therapeutics Raises Funding via Convertible Note Financing
TipRanks · 5d ago
Weekly Report: what happened at CERO last week (0518-0522)?
Weekly Report · 05/25 10:14
60 Degrees Pharma appoints Eric Francois to board
PUBT · 05/18 20:33
Weekly Report: what happened at CERO last week (0511-0515)?
Weekly Report · 05/18 10:14
CERo Therapeutics Hldgs Q1 EPS $(0.20) Beats $(1.00) Estimate
Benzinga · 05/15 22:04
CERo Therapeutics escalates CER-1236 Phase 1 trial to 10 million cells/kg cohort
PUBT · 05/11 12:15
CERO THERAPEUTICS HOLDINGS INC - NO DOSE-LIMITING TOXICITIES OBSERVED AT 4 × 10⁶ CELLS/KG DOSE IN SECOND COHORT
Reuters · 05/11 12:15
More
About CERO
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Webull offers CERo Therapeutics Holdings Inc stock information, including OTCMQB: CERO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERO stock methods without spending real money on the virtual paper trading platform.